Felzartamab in Late Antibody-Mediated Rejection

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

22 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-10-06

Study Completion Date

2024-03-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This prospective trial will assess the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamics and efficacy of the fully human CD38 monoclonal antibody felzartamab in kidney transplant recipients with late active or chronic-active ABMR. The study is designed as a randomized, controlled, double-blind pilot phase 2 trial. Participants will be randomized to receive either felzartamab or placebo for a period of six months, and then followed for another six months. After six and twelve months, study participants will be subjected to follow-up allograft biopsies.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)

NCT06685757

Antibody-mediated Rejection

RECRUITING PHASE3

Evaluation of Desensitization Protocols in HLA-incompatible Kidney-transplant Candidates

NCT03507348

End-stage Renal Disease Kidney Transplantation Hla-incompatible Kidney Transplant Candidates

TERMINATED NA

Transplant Antibody-Mediated Rejection: Guiding Effective Treatments

NCT03994783

Kidney Transplant Rejection Antibody-mediated Rejection

TERMINATED PHASE3

Daratumumab for Late Antibody-Mediated Rejection

NCT07081126

Kidney Tansplant Acute Rejection (AR) of Transplanted Kidney

RECRUITING NA

A Pilot Trial of Clazakizumab in Late ABMR

NCT03444103

Antibody-mediated Rejection

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This prospective bi-center study (University of Vienna, Charité Universitätsmedizin Berlin; Sponsor: Medical University of Vienna, Vienna, Austria; Funder: MorphoSys AG, Planegg, Germany) is an investigator-driven pilot trial designed to assess the safety\&tolerability (primary endpoint), pharmacokinetics, immunogenicity, pharmacodynamics and efficacy (preliminary assessment) of the fully human CD38 monoclonal antibody felzartamab in kidney transplant recipients diagnosed with late active or chronic-active antibody-mediated rejection (ABMR) after kidney transplantation.

Adult renal allograft recipients with anti-HLA donor-specific antibodies (DSA) and biopsy-proven ABMR (Banff 2019 classification) ≥180 days post-transplantation will be identified and recruited at the kidney transplantation outpatient services of the two center sites.

The primary endpoint will be safety and tolerability. Participants will be randomized to receive either felzartamab (intravenous administration) or placebo (1:1 randomization stratified by study site and according to ABMR categories) for a period of 6 months (administration of felzartamab/placebo at day 0, 7, 14, 21, and thereafter in 4-weekly intervals. After six (week 24) and twelve months (week 52), study participants will be subjected to follow-up allograft biopsies.

Primary goals of the trial are to assess the safety, pharmacokinetics and pharmacodynamics (peripheral blood plasma cell and natural killer cell depletion) of a 6-month course of treatment over a period of 12 months. The trial will in addition provide first data on efficacy (progression/activity of rejection, blood biomarkers) and potential associations of treatment with parameters reflecting clinical progression of allograft dysfunction, including the course of estimated glomerular filtration rate.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Antibody-mediated Rejection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Felzartamab

9 doses of felzartamab as an intravenous infusion over 6 treatment cycles at 28 days each. Dosing occurs every week in cycle 1 and every four weeks in cycles 2-6.

Group Type ACTIVE_COMPARATOR

Felzartamab

Intervention Type DRUG

Intravenous infusion in regular intervals over 6 months

Placebo

9 doses of placebo as an intravenous infusion over 6 treatment cycles at 28 days each. Dosing occurs every week in cycle 1 and every four weeks in cycles 2-6.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Intravenous infusion in regular intervals over 6 months

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Felzartamab

Intravenous infusion in regular intervals over 6 months

Intervention Type DRUG

Placebo

Intravenous infusion in regular intervals over 6 months

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

MOR202, CD38 monoclonal antibody 0.9% Saline

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Voluntary written informed consent
* Age \>18 years (maximum: 80 years)
* Functioning living or deceased donor allograft after ≥180 days post-transplantation
* eGFR ≥20 ml/min/1.73 m2 (CKD-EPI formula)
* HLA class I and/or II antigen-specific antibodies (preformed and/or de novo DSA).
* Active or chronic/active ABMR (±C4d in PTC) according to the Banff 2019 classification
* Molecular ABMR score (MMDx) ≥0.2

Exclusion Criteria

* Patients actively participating in another clinical trial
* Age ≤18 years
* Female subject is pregnant or lactating or not on adequate contraceptive therapy
* ABO-incompatible transplant
* Index biopsy results:
* T-cell-mediated rejection classified Banff grade ≥I
* De novo or recurrent severe thrombotic microangiopathy
* Polyoma virus nephropathy
* De novo or recurrent glomerulonephritis
* Acute rejection treatment ≤3 month before screening
* Previous treatment with other CD38 monoclonal antibodies (e.g. daratumumab)
* Previous treatment with other immunomodulatory monoclonal/polyclonal antibodies (e.g. CD20 Ab rituximab, IL-6/IL-6R Ab) ≤3 months before study treatment
* Total bilirubin \>2×the upper limit of normal \[ULN\], alanine transaminase and aspartate aminotransferase \>2·5×ULN
* Haemoglobin \<8 g/dL
* Thrombocytopenia: Platelets \<100 G/L
* Leukopenia: Leukocytes \<3 G/L
* Neutropenia: Neutrophils \< 1.5 G/L
* Hypogammaglobulinemia: Serum IgG \<400 mg/dL
* Active viral, bacterial or fungal infection precluding intensified immunosuppression
* Active malignant disease precluding intensified immunosuppressive therapy
* Latent or active tuberculosis (positive QuantiFERON-TB-Gold test)
* Administration of a live vaccine within 6 weeks of screening
* History of alcohol or illicit substance abuse
* Serious medical or psychiatric illness likely to interfere with participation in the study

Minimum Eligible Age

19 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No